tbuckley/cabot-search huggingface dataset:
TCT-47 Comparative Optical Coherent Tomographic analysis of in-stent neoatherosclerosis between 1st and 2nd generation drug-eluting stent
Authors: Mineok Chang, Jae-Hyung Roh, Pil Hyung Lee, Byeong Joo Bae, Hee-Soon Park, Se Hun Kang, Cheol Hyun Lee, Min Soo Cho, Jae Seok Bae, Yu Na Kim, Sung-Han Yoon, Jung-Min Ahn, Duk-Woo Park, Soo-Jin Kang, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2015)
Pre-Emptive or Reactive Treatment of Cutaneous Rash Induced by Epidermal Growth Factor Receptor Inhibitors: Does It Matter?
Authors: Gérard Zalcman, Solenn Brosseau, Valérie Gounant
Journal: Journal of Clinical Oncology (2015)

then shown to be safe and effective for stage-IV patients with EGFR mutations in the first-line setting in several randomized phase III trials comparing first-generation drugs (erlotinib or gefitinib) with platinum-based doublets. These trials reported similar progression-free survival (PFS) data ranging from 8.4 (WJTOG 3405) to 13.1 months (OPTIMAL), and overall survival (OS) data ranging from 19.3 (EURTAC) to 39 months (WTOG). 3-6 Two phase III trials comparing the second-generation irreversible EGFR inhibitor afatinib (LUX-Lung 3 and LUX-Lung 6) with chemotherapy confirmed this efficacy, with PFS rates of 11.1 and 11.0 months and OS rates of 28.2 and 23.1 months, respectively. 7,8 The pooled preplanned analysis also showed a significant 3-month OS advantage forafatinib comparedwithchemotherapy in patients with common mutations (del19 and Leu858Arg) combined. 9
Gas5 Exerts Tumor-suppressive Functions in Human Glioma Cells by Targeting miR-222
Authors: Xihe Zhao, Ping Wang, Jing Liu, Jian Zheng, Yunhui Liu, Jiajia Chen, Yixue Xue
Journal: Molecular Therapy (2015)

Aberrant expression of noncoding RNAs in glioma cells, including long noncoding RNAs (lncRNAs) and microRNAs, may participate in the progression of glioma. Encoded by Growth Arrest-Specific 5 (GAS5) gene, lncRNA Gas5 was reported to be a negative regulator for survival and proliferation of several cancers. Here, Gas5 is found to be downregulated in glioma specimens and U87 and U251 glioma cell lines. We showed that the introduction of Gas5 by plasmid transfection increased the expression of tumor suppressor Bcl-2-modifying factor (bmf) and Plexin C1 via directly targeting and reducing the expression of miR-222. Downregulated expression of miR-222 inhibited U87 and U251 cell proliferation and promoted the apoptosis by upregulating bmf. As downstream signaling molecules of bmf, Bcl-2 and Bax were involved in the process. Meanwhile, knockdown of miR-222 attenuated U87 and U251 cell migration and invasion by upregulating Plexin C1, and cofilin was a crucial regulator targeted by Plexin C1. Gas5 combined with the knockdown of miR-222 resulted in the smallest tumor volumes and the longest survivals of nude mice in vivo. In summary, we show that Gas5 suppresses tumor malignancy by downregulating miR-222, which may serve as a promising therapy for glioma. Aberrant expression of noncoding RNAs in glioma cells, including long noncoding RNAs (lncRNAs) and microRNAs, may participate in the progression of glioma. Encoded by Growth Arrest-Specific 5 (GAS5) gene, lncRNA Gas5 was reported to be a negative regulator for survival and proliferation of several cancers. Here, Gas5 is found to be downregulated in glioma specimens and U87 and U251 glioma cell lines. We showed that the introduction of Gas5 by plasmid transfection increased the expression of tumor suppressor Bcl-2-modifying factor (bmf) and Plexin C1 via directly targeting and reducing the expression of miR-222. Downregulated expression of miR-222 inhibited U87 and U251 cell proliferation and promoted the apoptosis by upregulating bmf. As downstream signaling molecules of bmf, Bcl-2 and Bax were involved in the process. Meanwhile, knockdown of miR-222 attenuated U87 and U251 cell migration and invasion by upregulating Plexin C1, and cofilin was a crucial regulator targeted by Plexin C1. Gas5 combined with the knockdown of miR-222 resulted in the smallest tumor volumes and the longest survivals of nude mice in vivo. In summary, we show that Gas5 suppresses tumor malignancy by downregulating miR-222, which may serve as a promising therapy for glioma.
Histological changes in cervical lymph nodes following clinical irradiation.
Authors: Burge Js
Journal: Journal of the Royal Society of Medicine (1975)

Abstract
Clinical radiation in man is shown to have similar effects to single dose irradiation in animals. While it is not possible by examining individual nodes to estimate the dose of radiation they have received, progressive changes with increasing doses can be seen leading to loss of lymphoid tissue and replacement by fibrous tissue. Functional changes probably occur, leading to loss of the filtering power of the nodes and their by-pass by anatomotic lymph channels. The purpose of this paper is in no way an appeal to discard radiation as a form of treatment for cancer. The destructive effects of radiation have been known form some time, but the significance of the regional nodes in the immune response to tumour has only recently been considered. A reappraisal is required of the way radiation therapy is given, so that as much as possbile of the immune mechanism may be left undamaged.
Prognostic significance of interleukin-8 (IL-8) and hepatocyte growth factor (HGF) in patients with head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation on a phase III trial.
Authors: D. Rischin, R. Fisher, K. Oliner, R. J. Young, H. Cao, G. A. McArthur, L. J. Peters, B. O'Sullivan, Q. Le
Journal: Journal of Clinical Oncology (2010)

5509 Background: HGF is a hypoxia induced protein that binds to its receptor MET to regulate expression of a variety of molecules including the cytokine IL-8. Both HGF and IL-8 are associated with angiogenesis, tumor growth, invasion, and metastasis. Methods: Patients with previously untreated stage III or IV HNSCC were randomized to receive definitive radiotherapy concurrently with cisplatin or cisplatin plus tirapazamine. There were no significant differences in any outcome parameter by randomization arm. Pretreatment plasma levels of HGF and IL-8 were measured using commercially available ELISA assays. Results: 557 out of 780 patients who received ≥ 60 Gy had samples available for both HGF and IL-8 measurements. The median IL-8 level was 6.48 pg/ml (range: 0 - 365).The median HGF level was 823 ng/ml (range: 190-42,300). Both higher plasma IL-8 and HGF levels were associated with worse overall survival (OS) and failure free survival (FFS) when analysed as continuous variables (log-transformed) as well as by median, tertile and quartile cut points. After adjustment for stage, tumor site, hemoglobin, ECOG PS and treatment arm, patients with low IL-8 (below the median) had better OS than patients with high IL-8 (HR = 0.58, p < 0.001). Similarly, HGF was also an independent significant prognostic factor for OS (HR= 0.74, p = 0.05). 160 patients with oropharyngeal cancer had HGF, IL-8 and p16INK4A data available. When the HGF and IL-8 results were combined in patients with HPV and p16INK4A negative oropharyngeal cancer, patients with HGF low/IL-8 low had significantly better OS than the combined HGF low/IL-8 high, HGF high/IL-8 low and the HGF high/IL-8 high subgroups (HR = 0.12, p=0.013). The 2-year OS in these 4 groups were 100%, 64%, 63% and 70% respectively. Conclusions: High plasma IL-8 levels and to a lesser extent high HGF levels are associated with an adverse prognosis in patients with locoregionally advanced HNSCC treated with chemoradiation. A low level of both plasma IL-8 and HGF identifies a subgroup of HPV negative oropharyngeal cancer with a more favorable prognosis. Supported by 1 R01 CA118582 and NHMRC project grant. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen Amgen
Protein-Fractionation Studies of a Mouse Thymoma&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: E. C. Gjessing, T. N. Warren, Curtis Floyd
Journal: JNCI Journal of the National Cancer Institute (1948)

Journal Article Protein-Fractionation Studies of a Mouse Thymoma Get access E. C. Gjessing, E. C. Gjessing Search for other works by this author on: Oxford Academic PubMed Google Scholar T. N. Warren, T. N. Warren Search for other works by this author on: Oxford Academic PubMed Google Scholar Curtis Floyd Curtis Floyd Biochemical Laboratory, University of Virginia, Charlottesville, Va. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 9, Issue 1, August 1948, Pages 43–46, https://doi.org/10.1093/jnci/9.1.43 Published: 01 August 1948 Article history Received: 11 May 1948 Published: 01 August 1948
Case 2: Meningeal Relapse in Hodgkin’s Disease
Authors: C.S. Chim, T.W. Shek, G.C. Ooi, R. Liang
Journal: Journal of Clinical Oncology (2000)

Article Tools Unusual Features of of Hodgkins's Disease Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2000.18.5.1153 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 10694569 Case 2: Meningeal Relapse in Hodgkin’s Disease C.S. ChimxC.S. ChimSearch for articles by this author , T.W. ShekxT.W. ShekSearch for articles by this author , G.C. OoixG.C. OoiSearch for articles by this author , R. LiangxR. LiangSearch for articles by this author Show More Queen Mary Hospital, University of Hong Kong, Hong Kong https://doi.org/10.1200/JCO.2000.18.5.1153 First Page Full Text PDF Figures and Tables © 2000 by American Society of Clinical Oncology
Abstract 18591: Obesity With and Without Metabolic Syndrome - Association With Coronary Artery Disease and Adverse Cardiovascular Outcomes
Authors: Edward Hulten, Marcio Bittencourt, Brian Ghoshhajra, Ravi Shah, Siddique Abbasi, Suhny Abbara, Khurram Nasir, Michael Blaha, Udo Hoffmann, Marcelo F Di Carli, Ron Blankstein
Journal: Circulation (2014)

Introduction: The relationship among body mass index (BMI), coronary artery disease (CAD), and cardiometabolic risk has not been thoroughly investigated among patients undergoing coronary computed tomography angiography (CCTA). Methods: Retrospective cohort study of all CCTA scans at two hospitals within Partners Healthcare (Boston, Massachusetts) from Sep 2004 to Oct 2011. We included all patients who underwent CCTA who were > 18 years old with available BMI and metabolic syndrome (MetS) risk factors. CCTA were categorized as normal, non-obstructive CAD ( 4. We evaluated a primary outcome of major adverse cardiovascular events (cardiovascular mortality, non-fatal myocardial infarction, unstable angina, or coronary revascularization >90 days after CCTA). Results: 1118 patients were included (57 ± 13 years old) with median follow-up 3.1 years. Increasing BMI was ...
Abstract 17995: Inhibition of Myofibroblast Differentiation by FOXO3a - Implications for Acute Myocardial Infarction and Cardiac Remodeling
Authors: Luise Holzhauser, Alexander Jenke, Kostas Savvatis, Mathias Grueger, Robert Schur, Diana Lindner, Dirk Westermann, Wolfgang Poller, Heinz-Peter Schultheiss, Carsten Skurk
Journal: Circulation (2014)

Introduction: Transdifferentiation of cardiac fibroblasts into myofibroblasts regulated by TGFβ/SMAD3 signaling is a major mechanism of scar formation and adverse remodeling following myocardial infarction. Hypothesis: We hypothesized that the transcription factor FOXO3a, a key regulator of cell differentiation, cycle and size, might inhibit this process. Methods: Acute myocardial infarction was induced in FOXO3-/- and WT mice (FVB) by permanent LAD ligation and myofibroblast transdifferentiation markers were assessed. FOXO3a-/- and WT cardiac fibroblasts were investigated in transdifferentiation assays ex vivo. FOXO3a gene transfer was performed with gain of function adenoviral vectors. IP/IF and Western blotting were used to test for a direct interaction between FOXO3a and SMAD3. Results: FOXO3a-/- mice had significantly higher survival rates compared to WT mice due to reduced rates of ventricle perforation. Myocardial expression of alpha smooth muscle actin (ASMA) and Collagen1A1 (Col1A1) was significantly enhanced in FOXO3a-/- mice 3 and 14 days post infarction. Moreover, Foxo3a-/- mice showed larger fibrotic areas following MI. In line with these results, cardiac fibroblasts isolated from FOXO3a-/- mice showed significantly enhanced expression levels of Col1A1 and ASMA 24 hours following stretch or TGF-β stimulation when compared to WT cells in vitro. Furthermore supernatants of FOXO3a -/- fibroblasts showed significantly higher protein expression of Col1A1 in (p&lt;0.01) while FOXO3a gene-transfer dose-dependently downregulated Col1A1. Immunfluorescence staining for ASMA protein was significantly attenuated following FOXO3a gene transfer in cardiac fibroblasts. Mechanistically, immunoprecipitation showed direct interaction of FOXO3a with SMAD3a that was enhanced following activation of the transcription factor leading to diminished SMAD3 downstream gene expression. Conclusions: Our results identify FOXO3a as a direct inhibitor of TGF- β regulated matrix remodeling via FOXO3a-SMAD3 interaction. FOXO3a regulates fibrosis and scar formation following myocardial infarction and thus targeting the FOXO3a-SMAD3 axis might be of therapeutic interest.
International, Randomized, Controlled Trial of Lamifiban (a Platelet Glycoprotein IIb/IIIa Inhibitor), Heparin, or Both in Unstable Angina
Journal: Circulation (1998)

Unstable angina and non-Q-wave myocardial infarction involve coronary arterial plaque rupture, platelet activation, and thrombus formation. This study tested the benefit of different doses of lamifiban (a platelet IIb/IIIa antagonist) alone and in combination with heparin in patients with these conditions to select the most promising lamifiban regimen for subsequent evaluation.At 273 hospitals in 20 countries, 2282 patients were randomly assigned to lamifiban (2x2 factorial design: low-dose [1 microg/min] with and without heparin versus high-dose [5 microg/min] with and without heparin) or to standard therapy (placebo and heparin). All patients received aspirin. The composite primary end point of death or nonfatal myocardial infarction at 30 days occurred in 11.7% of those receiving standard therapy, 10.6% receiving low-dose lamifiban, and 12.0% receiving high-dose lamifiban (P=0.668). By 6 months, this composite was lowest for those assigned to low-dose lamifiban (P=0.027) and intermediate for those assigned to high-dose lamifiban (P=0.450) compared with control (13.7%, 16.4%, and 17.9%, respectively). Compared with control, the combination of high-dose lamifiban and heparin resulted in more intermediate or major bleeding (12.1% versus 5.5%; P=0.002) and a similar rate of ischemic events. Conversely, low-dose lamifiban and heparin yielded similar bleeding rates as in the control group but fewer ischemic events at 6 months (12.6% versus 17.9%; P=0.025).In unstable angina and non-Q-wave infarction, platelet IIb/IIIa antagonism with lamifiban reduces adverse ischemic events at 6 months beyond that of aspirin and heparin therapy. The role of conjunctive heparin remains uncertain but appears more favorable with low-dose IIb/IIIa antagonism. Larger-scale study is needed to more reliably estimate these effects.
Say no to primary prophylaxis with implantable cardioverter-defibrillators in asymptomatic nonischemic dilated cardiomyopathy?**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
Authors: J.Vijay Jayachandran, Douglas P. Zipes
Journal: Journal of the American College of Cardiology (2003)
Neoplastic and Life-Span Effects of Chronic Exposure to Tritium. II. Rats Exposed In Utero
Authors: Daniel F. Cahill, James F. Wright, James H. Godbold, Jerrold M. Ward, John W. Laskey, Edythalena A. Tompkins
Journal: JNCI Journal of the National Cancer Institute (1975)

Journal Article Neoplastic and Life-Span Effects of Chronic Exposure to Tritium. II. Rats Exposed In Utero Get access Daniel F. Cahill, Daniel F. Cahill Search for other works by this author on: Oxford Academic PubMed Google Scholar James F. Wright, James F. Wright Search for other works by this author on: Oxford Academic PubMed Google Scholar James H. Godbold, James H. Godbold Search for other works by this author on: Oxford Academic PubMed Google Scholar Jerrold M. Ward, Jerrold M. Ward Search for other works by this author on: Oxford Academic PubMed Google Scholar John W. Laskey, John W. Laskey Search for other works by this author on: Oxford Academic PubMed Google Scholar Edythalena A. Tompkins Edythalena A. Tompkins Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 55, Issue 5, November 1975, Pages 1165–1169, https://doi.org/10.1093/jnci/55.5.1165 Published: 01 November 1975 Article history Received: 13 March 1975 Accepted: 02 June 1975 Published: 01 November 1975
Factors associated with spontaneous clearance of chronic hepatitis C virus infection
Authors: Naomi Bulteel, Prasanna Partha Sarathy, Ewan Forrest, Adrian J. Stanley, Hamish Innes, Peter R. Mills, Heather Valerio, Rory N. Gunson, Celia Aitken, Jude Morris, Ray Fox, Stephen T. Barclay
Journal: Journal of Hepatology (2016)
Cardioprotective therapy and sodium-hydrogen exchange inhibition: current concepts and future goals**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
Authors: Ian B.A. Menown, A.A.Jennifer Adgey
Journal: Journal of the American College of Cardiology (2001)
Preradiotherapy Computed Tomography as a Predictor of Local Control in Supraglottic Carcinoma
Authors: Anthony A. Mancuso, Suresh K. Mukherji, Ilona Schmalfuss, William Mendenhall, James Parsons, Frank Pameijer, Robert Hermans, Paul Kubilis
Journal: Journal of Clinical Oncology (1999)

PURPOSE: To determine the utility of pretreatment computed tomography (CT) for predicting primary site control in patients with supraglottic squamous cell carcinoma (SCC) treated with definitive radiotherapy (RT). MATERIALS AND METHODS: Pretreatment CT studies in 63 patients were reviewed. Minimum length of follow-up was 2 years. Local recurrence and treatment complications resulting in permanent loss of laryngeal function were documented. Tumor volume was calculated using a computer digitizer, and pre-epiglottic space (PES) spread was estimated. The data were analyzed using a combination of Fisher's exact test, logistic regression modeling, and multivariate analyses. Five-year local control rates were calculated using the product-limit method. RESULTS: Local control rates were inversely and roughly linearly related to tumor volume, although there seemed to be a threshold volume at which primary site prognosis diminished. Local control was 89% in tumors less than 6 cm 3 and 52% when volumes were ≥ 6 cm 3 (P = .0012). The likelihood of maintaining laryngeal function also varied with tumor volume: 89% for tumors less than 6 cm 3 and 40% for tumors ≥ 6 cm 3 (P = .00004). Pre-epiglottic space involvement by tumor of ≥ 25% was associated with a reduced chance of saving the larynx (P = .0076). Multivariate analyses revealed that only tumor volume independently altered these end points. CONCLUSION: Pretreatment CT measurements of tumor volume permits stratification of patients with supraglottic SCC treated with RT alone (which allows preservation of laryngeal function) into groups in which local control is more likely and less likely. Pre-epiglottic space spread is not a contraindication to using RT as the primary treatment for supraglottic SCC.
Abstract P3-02-05: Qatar experience of Standard risk breast cancer screening program (BCSP)
Authors: Salha Bujassoum, Reena Alassam, Hekmat Bugrein, Mufid Elmistiri
Journal: Cancer Research (2015)

Abstract Background Qatar has one of the highest age-adjusted breast cancer incidences in the Arab world. Although this is much lower than the incidence in the West. Breast cancer incidence in Qatar was 45 per 100,000 in 2003-2007.These higher incidence rates in Qatar are mainly due to the growing population. The prevalent age group, for Qatari and non-Qatari patients, was 40-50 years old. This suggests that the age-specific incidence of breast cancer in Qatari women is unlike the pattern usually seen in Western nations where median age at diagnosis is 61 years, moreover the diagnosis is often at advanced stages of breast cancer. These factors led to establishment the first hospital based (BCSP) in Qatar. It uses a distributed model of mammography service. The program launched 2008, accepts eligible asymptomatic women at ages 40 - 69 years. Methods A retrospective study was done during the period from April 2008 –December 2013. Our aim is to describe our experience of (BCSP) in Qatar and to monitor performance indicators. Our (BCSP) includes an office call and recall as well as triple assessment. We also discuss positive cases in multi-disciplinary meeting. Results Total number of screened women was 4264 with an increasing participation, year by year. Out of these, Qatari patient’s accounts for 1145, and non Qatari for 3119. The age group of cases was (43-51). Total breast biopsies were 82, of which 45 were positive of breast carcinomas, (37) invasive ductal carcinoma, (8) noninvasive ductal carcinoma. The Invasive cancer detection rate was 8.2 %. The positive predictive value (PPV) was 46%. Sensitivity value has improved from 51% in 2008 to 70% in 2012 as well as specificity value that has increased from 77% in 2008 to 83% in 2012. Conclusion Public acceptance of (BCSP) in Qatar gradually increased and detection rates are higher than western countries. We’re detecting biologically aggressive tumors at younger age groups. We’ve a unique population and we need to utilize our data and evidence based medicine to guide policy makers and women to make the correct decision towards (BCSP). Citation Format: Salha Bujassoum, Reena Alassam, Hekmat Bugrein, Mufid Elmistiri. Qatar experience of Standard risk breast cancer screening program (BCSP) [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P3-02-05.